早期非小细胞肺癌手术与SBRT治疗后的死亡率分析
该研究基于美国国家癌症数据库分析2004-2013年cT1-T2aN0M0非小细胞肺癌患者,比较手术与立体定向体部放疗后的30天和90天死亡率。结果显示手术死亡率高于SBRT,且差异随年龄增长而扩大,尤其70岁以上患者差异最大。
要点
- 手术较SBRT的30天和90天死亡率更高,匹配后差异增大。
- 年龄越大,手术与SBRT的死亡率差异越显著。
- 手术切除范围越大,死亡率风险越高。
核心结论
- 手术与SBRT的30天和90天治疗后死亡率差异随年龄增长而增加,70岁以上患者差异最大且有利于SBRT。
- 这些代表性死亡率数据可帮助适合两种治疗的早期NSCLC患者进行共享决策。
研究设计与样本
- 研究基于美国国家癌症数据库,纳入2004-2013年诊断为cT1-T2a、N0、M0的非小细胞肺癌患者,接受手术或SBRT治疗。
- 共识别76,623例手术患者(78%肺叶切除,20%亚肺叶切除,2%全肺切除)和8,216例SBRT患者。
- 采用Cox回归和倾向评分匹配分析比较30天和90天治疗后死亡率。
主要发现
- 未匹配队列中,手术 vs SBRT的30天死亡率为2.07% vs 0.73%(绝对差1.34%,P<0.001),90天为3.59% vs 2.93%(绝对差0.66%,P<0.001)。
- 倾向评分匹配的27,200例患者中,30天死亡率手术 vs SBRT为2.41% vs 0.79%(绝对差1.62%,P<0.001),90天为4.23% vs 2.82%(绝对差1.41%,P<0.001)。
- 年龄交互作用显著(30天和90天P<0.001):71-75岁30天绝对差1.87%、90天2.02%;76-80岁30天2.80%、90天2.59%;>80岁30天3.03%、90天3.67%(所有P≤0.001)。
- 多变量风险比显示手术死亡率随切除范围增加而升高:亚肺叶切除30天和90天HR分别为2.85和1.37,肺叶切除3.65和1.60,全肺切除14.5和5.66(所有P<0.001)。
临床怎么用
- 对于早期NSCLC患者,尤其是70岁以上,选择手术或SBRT时应考虑术后早期死亡风险差异。
- 共享决策中可参考年龄和切除范围相关的死亡率数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose In early-stage non-small cell lung cancer (NSCLC), post-treatment mortality may influence the comparative effectiveness of surgery and stereotactic body radiotherapy (SBRT), with implications for shared decision making among high-risk surgical candidates. We analyzed early mortality after these interventions using the National Cancer Database. Patients and Methods We abstracted patients with cT1-T2a, N0, M0 NSCLC diagnosed between 2004 and 2013 undergoing either surgery or SBRT. Thirty-day and 90-day post-treatment mortality rates were calculated and compared using Cox regression and propensity score-matched analyses. Results We identified 76,623 patients who underwent surgery (78% lobectomy, 20% sublobar resection, 2% pneumonectomy) and 8,216 patients who received SBRT. In the unmatched cohort, mortality rates were moderately increased with surgery versus SBRT (30 days, 2.07% v 0.73% [absolute difference (Δ), 1.34%]; P < .001; 90 days, 3.59% v 2.93% [Δ, 0.66%]; P < .001). Among the 27,200 propensity score-matched patients, these differences increased (30 days, 2.41% v 0.79% [Δ, 1.62%]; P < .001; 90 days, 4.23% v 2.82% [Δ, 1.41%]; P < .001). Differences in mortality between surgery and SBRT increased with age, with interaction P < .001 at both 30 days and 90 days (71 to 75 years old: 30-day Δ, 1.87%; 90-day Δ, 2.02%; 76 to 80 years old: 30-day Δ, 2.80%; 90-day Δ, 2.59%; > 80 years old: 30-day Δ, 3.03%; 90-day Δ, 3.67%; all P ≤ .001). Compared with SBRT, surgical mortality rates were higher with increased extent of resection (30-day and 90-day multivariate hazard ratio for mortality: sublobar resection, 2.85 and 1.37; lobectomy, 3.65 and 1.60; pneumonectomy, 14.5 and 5.66; all P < 0.001). Conclusion Differences in 30- and 90-day post-treatment mortality between surgery and SBRT increased as a function of age, with the largest differences in favor of SBRT observed among patients older than 70 years. These representative mortality data may inform shared decision making among patients with early-stage NSCLC who are eligible for both interventions.
引用
- Stokes WA, Bronsert MR, Meguid RA, et al. Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2018. PMID: 29346041. doi:10.1200/JCO.2017.75.6536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。